Valora Therapeutics Secures $30 Million Seed Financing for Glyco-immune Checkpoint Platform from Carolyn Bertozzi's Lab
Valora Therapeutics has successfully raised $30 million in seed financing aimed at advancing its novel glyco-immune checkpoint platform for immunotherapy. The startup, which emerged from the lab of Nobel laureate Carolyn Bertozzi, is co-founded by Bertozzi along with Jessica Stark, Miguel Garcia-Guzman, and the Koch Institute at MIT. This funding will support the development of the company's innovative technology, which aims to enhance immunotherapy treatments. The announcement highlights Valora's commitment to transforming cancer treatment through its proprietary AbLec technology.
Sources
Nature Biotechnology
Each year, we highlight companies that have received sizeable early-stage funding in the previous year. Gate Bioscience wants to tailor gates that stop problematic proteins at the source https://t.co/O5yPNUoSoS
San Diego Biotech NetworksChasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab https://t.co/OgGclcg0MI #biotech #news
Carolyn BertozziCongratulations to the Valora Therapeutics team on an exciting launch; it is a privilege to work with cofounders @JessicaCStark @kochinstitute @MIT and biotech veteran/CEO Miguel Garcia-Guzman bringing the #AbLec technology to patients. #glycotime https://t.co/WetaVEMSjq